City of Hope’s Ravi Salgia, M.D., Ph.D., honored by the IACA
June 2, 2017 | by Letisia Marquez
Ravi Salgia, M.D., Ph.D., whose accomplishments as a medical oncologist and researcher have helped define modern cancer medicine, was celebrated on June 3 for his contributions to the field.
The Indo-American Cancer Association (IACA) honored Salgia with the IACA Award for Outstanding Contributions to Oncology during its annual meeting, which took place during the American Society of Clinical Oncology’s (ASCO) 2017 annual meeting in Chicago.
Salgia, the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope's comprehensive cancer center, also served as the keynote speaker at the IACA meeting.
“It is an honor to receive this award from the IACA,” Salgia said. “City of Hope appreciates IACA’s recognition of the critical oncology research that is underway.”
Salgia has over 25 years of accomplishments in translational research and the development of targeted therapies to improve the quality of life and survival of cancer patients, especially as related to small cell lung cancer, the IACA noted.
Salgia was the first to clone the focal adhesion protein paxillin and also localize the gene to 12q24, the organization added. His laboratory also identified the gain-of-function mutations of paxillin in lung cancer, defined receptor tyrosine kinases and identified unique targets in lung cancer such as MET/RON and EPHB4 receptor tyrosine kinases.
Salgia plays a key leadership role in the expansion of clinical programs at City of Hope’s Duarte, California, campus and in its clinics throughout Southern California, and has helped lead the integration of state-of-the-art therapeutics with leading-edge research. Salgia works closely with faculty to support both basic research and clinical studies aimed at discovering new cancer treatments.
Board-certified in both internal medicine and medical oncology, Salgia serves on various panels for the National Cancer Institute. He has consistently received research grants from the National Institutes of Health for his research work and has been awarded several invention discoveries and patents related to his work. He is the current chief editor for Cancer Commons, and the co-chief editor for the Journal of Carcinogenesis. Salgia also serves on the editorial advisory board of four additional journals. He has authored 286 peer-reviewed articles, reviews and editorials, one book and 34 book chapters.
Salgia is frequently invited to present his work at national and international conferences and symposia and is the recipient of several honors and awards.
At the 2017 ASCO meeting, Salgia also chaired two sessions, one on value-based medicine and integration of tumor biology and another on tumor biology.
, Thank you for subscribing to Physician News.
Check your inbox for the latest breakthroughs, clinical trials, and CME opportunities.
City of Hope Will Offer First FDA-approved CAR-T Cell Therapy for Patients with Some Types of Lymphoma
Molecularly Intertwined: City of Hope and Caltech Collaborate to Fight Leukemia and Autoimmune Disease